🎉 M&A multiples are live!
Check it out!

Emcure Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Emcure Pharmaceuticals and similar public comparables like Julphar, Vivoryon Therapeutics, and Benevolent AI.

Emcure Pharmaceuticals Overview

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics.


Founded

1981

HQ

India
Employees

11.1K+

Website

emcure.com

Financials

LTM Revenue $915M

LTM EBITDA $172M

EV

$2.1B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Emcure Pharmaceuticals Financials

Emcure Pharmaceuticals has a last 12-month revenue of $915M and a last 12-month EBITDA of $172M.

In the most recent fiscal year, Emcure Pharmaceuticals achieved revenue of $764M and an EBITDA of $147M.

Emcure Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Emcure Pharmaceuticals valuation multiples based on analyst estimates

Emcure Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $689M $764M XXX XXX XXX
Gross Profit $410M $426M XXX XXX XXX
Gross Margin 60% 56% XXX XXX XXX
EBITDA $139M $147M XXX XXX XXX
EBITDA Margin 20% 19% XXX XXX XXX
Net Profit $76.9M $61.8M XXX XXX XXX
Net Margin 11% 8% XXX XXX XXX
Net Debt $233M $248M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Emcure Pharmaceuticals Stock Performance

As of April 15, 2025, Emcure Pharmaceuticals's stock price is INR 919 (or $11).

Emcure Pharmaceuticals has current market cap of INR 174B (or $2.0B), and EV of INR 183B (or $2.1B).

See Emcure Pharmaceuticals trading valuation data

Emcure Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.1B $2.0B XXX XXX XXX XXX $0.43

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Emcure Pharmaceuticals Valuation Multiples

As of April 15, 2025, Emcure Pharmaceuticals has market cap of $2.0B and EV of $2.1B.

Emcure Pharmaceuticals's trades at 2.3x LTM EV/Revenue multiple, and 12.3x LTM EBITDA.

Analysts estimate Emcure Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Emcure Pharmaceuticals and 10K+ public comps

Emcure Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.1B XXX XXX XXX
EV/Revenue 2.4x XXX XXX XXX
EV/EBITDA 12.9x XXX XXX XXX
P/E 27.0x XXX XXX XXX
P/E/Growth 1.1x XXX XXX XXX
EV/FCF 37.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Emcure Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Emcure Pharmaceuticals Valuation Multiples

Emcure Pharmaceuticals's NTM/LTM revenue growth is 11%

Emcure Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $33K for the same period.

Over next 12 months, Emcure Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Emcure Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Emcure Pharmaceuticals and other 10K+ public comps

Emcure Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 11% XXX XXX XXX XXX
EBITDA Margin 19% XXX XXX XXX XXX
EBITDA Growth 6% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 30% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $33K XXX XXX XXX XXX
S&M Expenses to Revenue 8% XXX XXX XXX XXX
G&A Expenses to Revenue 4% XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 48% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Emcure Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Emcure Pharmaceuticals M&A and Investment Activity

Emcure Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Emcure Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Emcure Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Emcure Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Emcure Pharmaceuticals

When was Emcure Pharmaceuticals founded? Emcure Pharmaceuticals was founded in 1981.
Where is Emcure Pharmaceuticals headquartered? Emcure Pharmaceuticals is headquartered in India.
How many employees does Emcure Pharmaceuticals have? As of today, Emcure Pharmaceuticals has 11.1K+ employees.
Is Emcure Pharmaceuticals publicy listed? Yes, Emcure Pharmaceuticals is a public company listed on BOM.
What is the stock symbol of Emcure Pharmaceuticals? Emcure Pharmaceuticals trades under 544210 ticker.
When did Emcure Pharmaceuticals go public? Emcure Pharmaceuticals went public in 2024.
Who are competitors of Emcure Pharmaceuticals? Similar companies to Emcure Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Emcure Pharmaceuticals? Emcure Pharmaceuticals's current market cap is $2.0B
What is the current revenue of Emcure Pharmaceuticals? Emcure Pharmaceuticals's last 12-month revenue is $915M.
What is the current EBITDA of Emcure Pharmaceuticals? Emcure Pharmaceuticals's last 12-month EBITDA is $172M.
What is the current EV/Revenue multiple of Emcure Pharmaceuticals? Current revenue multiple of Emcure Pharmaceuticals is 2.3x.
What is the current EV/EBITDA multiple of Emcure Pharmaceuticals? Current EBITDA multiple of Emcure Pharmaceuticals is 12.3x.
What is the current revenue growth of Emcure Pharmaceuticals? Emcure Pharmaceuticals revenue growth between 2023 and 2024 was 11%.
Is Emcure Pharmaceuticals profitable? Yes, Emcure Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.